FDA review of INOVIO's INO-3107 for RRP targets Oct 2026 approval; positive Phase 3 VGX-3100 results in China reported.

INOVIO's FDA review for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP), is progressing with a target approval date of October 30, 2026. The company is preparing for commercial launch and has engaged partners for sales and distribution. Additionally, INOVIO's partner ApolloBio reported positive Phase 3 trial results for VGX-3100, a treatment for cervical dysplasia, in China. INOVIO also presented promising data on next-generation DNA medicines and expects current funds to support operations through early 2027, including a potential INO-3107 launch if approved.